AUAUniversity

This podcast webinar will introduce attendees to current diversity initiatives within urology. Panelists representing these programs will discuss the benefits of promoting diversity in urology, how their initiatives began, available resources and what urology residency programs and medical schools can do to promote diversity.

How to Manage a 65 Year Old Man with Bothersome LUTS and Underactive Bladder by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31224

Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.

Upon completion of this activity, participants will be able to:

1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.

2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.

3. Discuss the impact of shared-decision making on patient and on patient-clinician communication.

4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.

Multidisciplinary Discussion On Fertility, Hypogonadism & Sexual Function For Testis Cancer Patients by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31223

Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.

Upon completion of this activity, participants will be able to:

1. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition.

2. Discuss the current clinical trials associated with PARP inhibitors.

3. Describe the patient populations associated with each trial.

4. State the clinical outcomes for each trial.

Controversies In Urology - Robotic Kidney Transplantation by American Urological Association

Panel Discussion - Infection And Urologic Implants by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31198

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.

Upon completion of this activity, participants will be able to:

1. Review recommended criteria for genetic testing of prostate cancer patients and the options for testing these men.

2. Explain importance of testing for germline pathogenic variants and their implication for utilizing novel targeted therapies such as PARP inhibitors and for cascade testing among patient family members.

3. Identify men with BRCA1/2 pathogenic variants and variants in other key inherited syndromes, regarding their prostate cancer and other cancer risk, and implement strategies for cancer screening and management.

This educational series is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30861

In 2020, the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline was released and will provide critical guidance as the management of advanced prostate cancer patients continues to expand.

To increase urologists understanding of how to translate the latest scientific advances and the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline into their clinical practice, the featured 60-minute panel discussion includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of mHSPC. Faculty will highlight the management of patients with advanced prostate cancer and how therapeutic options have been incorporated into evidence-based guidelines.

Learning Objectives:

At the conclusion of the activity, participants will be able to:

1. Identify the active agents and their mechanism of action in the management of metastatic hormone sensitive prostate cancer (mHSPC).

2. Review the evidence and outcomes on the treatment of mHSPC as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.

3. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice.

4. Analyze breakthrough treatments in the management of advanced and mHSPC.

5. Describe the indications and combinations for treatment with approved agents in the management of mHSPC.

Impacts of COVID-19 on Urology Training and Education by American Urological Association